期刊文献+

早期胰岛素泵治疗对新诊断的2型糖尿病患者血胰升血糖素样肽1的影响 被引量:5

The effect of early CSII on serum GLP-1 in newly-diagnosed type 2 diabetic patients
原文传递
导出
摘要 目的观察早期胰岛素泵治疗对新诊断的2型糖尿病(T2DM)患者血胰升血糖素样肽1(GLP-1)的影响。方法选择T2DM患者100例,根据病程分为两组:试验组40例,为新诊断的T2DM患者(病程<1年);对照组60例,为T2DM患者(病程1~10年)。两组均使用胰岛素泵持续皮下输注超短效胰岛素门冬胰岛素(诺和锐)2周。比较两组FPG、2hPG、糖化血清白蛋白(GA)、空腹GLP-1、FC-P等变化情况及其相关性。结果治疗后两组FPG、2hPG、GA、FC-P、空腹GLP-1的差异均有统计学意义(P<0.05);两组治疗前后变化量比较有统计学意义(P<0.05)。GLP-1与FC-P呈正相关,与FPG、2hPG及GA呈负相关。结论早期胰岛素泵治疗能够很好控制血糖,促进胰岛功能恢复。对于新诊断的糖尿病患者,GLP-1显著升高,表明胰岛素泵早期治疗在改善β细胞功能、部分恢复餐后胰岛素早时相分泌方面有重要作用,而这种作用在1年以上病程的患者中表现相对不明显。 Objective To observe the effect of early CSII (continuous subcutaneous insulin infusion) with aspart insulin on serum GLP-1 (glucagon-like peptide-1). Methods The 100 T2DM patients treated with CSII of aspart insulin were divided into 2 groups: study group (n=40, newly diagnosed) and control group (n= 60, 1 10 years course). Health group (n=30) was defined as healthy subject by health examination. FPG, 2hPG, fasting c-peptide and glucagon were assayed and compared between three groups. Results The posttreatment increments in GLP-1, F-CP and GA were higher in study group [ (0. 72 ± 0. 35 ) mmol/L, ( 0. 65 ± 0. 21 ) nmol/L, (6. 354±2.87) mmol/L, respectively] than in control group E(0. 41±0. 29) retool/L, (0. 36±0. 12) nmol/L, (3. 62± 1.05) mmol/L, respectively] (all P〈 0. 05). The posttreatment decrement in 2hPG and FPG were higher in study group than in control group (P〈0.05). Serum GLP-1 was positively correlated with F-CP and negatively with FPG, 2hPG and GA (all P〈0.05). Conclusions Early CSII used in T2DM may restore the serum GLP-1 and improve β-cell funetion.
作者 韩瑛 吕肖锋
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2011年第2期122-124,共3页 Chinese Journal of Diabetes
关键词 糖尿病 2型 胰岛素泵 胰升血糖素样肽1 糖化血清白蛋白 Diabetes mellitus, type 2 Insulin pump Glucagon-like peptide-1 Glycated albumin
  • 相关文献

参考文献5

  • 1Beckman LM,Beckman TR,Earthman CP.Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass proeedure:a review.J Am Diet Assoc,2010,110:571-584.
  • 2Drucker D.Enhacing incretin action for the treatment of type 2 diabetes.Diabetes Care,2008,26:2929-2940.
  • 3Li LX,MacDonald PE,Ahn DS,et al.Role of phosphatidyl-inositol 3-kinasegamma in the beta-celI:interactionswithglucagon-likepeptide-1.Endocrinology,2006,147:3318-3325.
  • 4MacDonal PE,Salapatek AM,Wheeler MB.Glucagon like peptide-1 receptor activation antagonizes volt-age-dependent repolorizing K+current s in beta-ceils:apossible glucose-dependent insulin mechanism.Diabetes,2010,51:443-447.
  • 5Valverde I,Wang GS,Burghardt K,et al.Bioaetive GLP-1 in gut,receptor expression in pancreas,and insulin response to GLP-1 in diabetes prone ras.Endocrine,2004,23:77-84.

同被引文献37

引证文献5

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部